WEST LAFAYETTE, Ind., June 05, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced ...
New indication authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) expands access to lutetium177 ...
A panel of experts offers guidance for selecting patients with mCRPC for treatment with 177Lu-PSMA-617 and for managing treatment-related toxicities. The treatment is approved for use in men with ...
Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...
Association between SPECT/CT total tumor volume (TTV) and new lesions (NLs) in early cycles of 177Lu-PSMA-617 (LuPSMA) and progression-free and overall survival (PFS and OS) in men with metastatic ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some high-grade prostate cancers, such as intraductal carcinoma of the prostate, are not clearly visible on PSMA PET. For patients with intraductal carcinoma of the prostate (IDC-P), prostate-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results